These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 2368713)
21. [Drug committees are necessary, according to the SNS reference group]. Allebeck P Lakartidningen; 2005 Apr 4-10; 102(14):1070. PubMed ID: 15892479 [No Abstract] [Full Text] [Related]
22. Rational drug use (II): Hospital drug and therapeutics committees. Manyemba J; Dzuda C; Nyazema NZ Cent Afr J Med; 2000 Sep; 46(9):256-9. PubMed ID: 11320773 [No Abstract] [Full Text] [Related]
23. Role playing using a simulated pharmacy and therapeutics committee model. Fletcher HP; Popovich NG Am J Pharm Educ; 1977 Aug; 41(3):282-5. PubMed ID: 10305978 [No Abstract] [Full Text] [Related]
24. A strengthened pharmacy and therapeutics committee offers new opportunities for pharmacists. Francke DE Hospitals; 1967 Nov; 41(21):93-4 passim. PubMed ID: 6060942 [No Abstract] [Full Text] [Related]
25. [Drug committees in Sweden]. Barkman R Tidsskr Nor Laegeforen; 1970 Jan; 90(1):1-3. PubMed ID: 5448711 [No Abstract] [Full Text] [Related]
27. Pharmacy curriculum and health care needs in Saudi Arabia. Al-Sowaygh IA; Morad AR; Abdullah ME Am J Pharm Educ; 1981 Feb; 45(1):20-4. PubMed ID: 10251225 [No Abstract] [Full Text] [Related]
28. P & T committees and the hospital formulary. Evans PJ; Standish RC; Bell JE Hosp Formul; 1983 Sep; 18(9):892-5. PubMed ID: 10262367 [No Abstract] [Full Text] [Related]
29. P & T Committee roundtable discussion: Eastern region. Part I. Fine DJ; Guild RT; Kleinmann K; Kupersmith J Hosp Formul; 1984 Jun; 19(6):469-72, 475-6. PubMed ID: 10266565 [TBL] [Abstract][Full Text] [Related]
30. P & T Committee roundtable discussion: Eastern region Pt. II. Fine DJ; Guild RT; Kleinmann K; Kupersmith J Hosp Formul; 1984 Jul; 19(7):561-4, 568-70. PubMed ID: 10267389 [TBL] [Abstract][Full Text] [Related]
31. [The drug committees will play a key role]. Gennser M Lakartidningen; 1993 Nov; 90(46):4078, 4083. PubMed ID: 8259004 [No Abstract] [Full Text] [Related]
32. [Are the drug committees sold?]. Bystedt T; Gustavsson R Lakartidningen; 1993 Oct; 90(41):3518, 3523. PubMed ID: 8231491 [No Abstract] [Full Text] [Related]
33. Some research opportunities in hospital pharmacy. Wertheimer AI Am J Hosp Pharm; 1981 Oct; 38(10):1534-6. PubMed ID: 7294056 [TBL] [Abstract][Full Text] [Related]
34. Potential conflict of interest of a pharmacy and therapeutics committee member. Am J Hosp Pharm; 1989 Oct; 46(10):2047-9; discussion 2049-51. PubMed ID: 2816960 [No Abstract] [Full Text] [Related]
35. [Future drug committees--institutions for cooperation and information]. Odeberg H; Lenhoff K Lakartidningen; 1989 Jan; 86(1-2):34. PubMed ID: 2911227 [No Abstract] [Full Text] [Related]
36. The critical path initiative: what is in it for P&T Committees? Hirschmann JL Manag Care Interface; 2006 Oct; 19(10):14. PubMed ID: 17117594 [No Abstract] [Full Text] [Related]
37. [A new model of drug committees' activities developed in Gothenburg]. Iwarson S Lakartidningen; 1996 Jul; 93(30-31):2649-50. PubMed ID: 8765777 [No Abstract] [Full Text] [Related]
38. A survey of Pharmacy and Therapeutic committees across Canada: scope and responsibilities. Mittmann N; Knowles S Can J Clin Pharmacol; 2009; 16(1):e171-7. PubMed ID: 19242000 [TBL] [Abstract][Full Text] [Related]
39. [Drug committees, choice of drugs and drug information]. Lundh B Lakartidningen; 1988 Nov; 85(44):3641-3. PubMed ID: 3199994 [No Abstract] [Full Text] [Related]